News

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
FDA Protocol Review Completed ~ ~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company" ...
Second Quarter Report 2025
EBITDA amounted to KSEK - 8 875 (5 595).EBIT amounted to KSEK -10 992 (3 715).Cash flow from operating activities amounted to KSEK -11 631 (-1 112).Earnings per share amounted to SEK ...